Home | Welcome to Contract Pharma   
Last Updated Monday, May 20 2013
Print

Financial Reports

Related Searches:

Filter by:

April 27, 2012
Product sales up 19%   Read More »
April 26, 2012
Revenues drop 11%   Read More »
April 26, 2012
Pharmaceutical sales up 2%   Read More »
April 25, 2012
Revenues up 9% in the quarter   Read More »
April 25, 2012
Zyprexa patent expirations impact results   Read More »
April 24, 2012
1Q revenues up 10%   Read More »
April 24, 2012
Pharmaceutical sales up 2%   Read More »
April 19, 2012
Advate, Gammagard Liquid drive BioScience growth   Read More »
April 18, 2012
1Q Revenues: $9.4 billion (+4%) 1Q Earnings: $1.2 billion (+44%) Comments: Proprietary pharma revenues were up 7% to $4.1 billion, driven by Humira (+17% to $1.9 billion). The established pharma revenues (ex-U.S.) was down 2% to $1.3 billion.…   Read More »
April 17, 2012
1Q Revenues: $16.1 billion (flat) 1Q Earnings: $3.9 billion (+12%) Comments: Pharma sales were $6.3 billion, up 1%, with a slight negative impact from currency rates. Consumer sales dropped 2% to $3.6 billion, as the company continues to struggle w…   Read More »
March 9, 2012
Terminated supply pact impact results   Read More »
March 9, 2012
Revenues climb 22% in 2011   Read More »
February 16, 2012
Revenues up 5%, CFO named   Read More »
February 16, 2012
Contract manufacturing revenues account for 79% of 4Q11 sales   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On